Tofogliflozin is primarily used in the treatment of type 2 diabetes mellitus. It works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys, which helps to reduce blood glucose levels by promoting the excretion of glucose through urine. This mechanism of action makes it effective in managing hyperglycemia without directly stimulating insulin secretion. Additionally, it has shown potential benefits in reducing body weight and blood pressure, which are common comorbidities in diabetic patients. Tofogliflozin is often prescribed as part of a comprehensive diabetes management plan, including diet and exercise. It is also being studied for its potential cardiovascular benefits, particularly in reducing the risk of heart failure in diabetic patients.